Loading stock data…
$15.65-0.30 (-1.88%)
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific.
Ultragenyx Pharmaceutical Inc. in the Healthcare sector is trading at $15.65 with a market capitalization of $1.5B. Wall Street consensus targets $26.25 (20 analysts), implying a +67.7% move over the next 12 months. The stock is currently near its 52-week low of $12.73, remaining 32.2% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $214.00M↑ | $136.00M↓ | $207.28M↑ | $159.93M↓ | $167.00M |
| Gross Profit | $180.00M↑ | $106.00M↓ | $177.93M↑ | $131.94M↓ | $144.00M |
| Operating Income | -$75.00M↑ | -$169.00M↓ | -$113.28M↑ | -$170.89M↓ | -$108.00M |
| Net Income | -$92.00M↑ | -$185.00M↓ | -$128.56M↑ | -$180.41M↓ | -$115.00M |
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, E...